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doi:10.1016/j.jfma.2011.06.024Background/Purpose: Esophageal variceal hemorrhaging is potentially life threatening for
long-term survivors of biliary atresia. We evaluated the feasibility of less-invasive parameters
for predicting the presence of clinically significant esophageal variceal bleeding in biliary
atresia patients.
Methods: A total of 30 patients aged 108e5314 days (median Z 285 days) with biliary atresia
underwent a magnetic resonance examination with fast spin-echo T2-weighted imaging and
spin-echo, T1-weighted images with fat saturation after use of a contrast medium on a 1.5-tesla
scanner. The splenic length-platelet ratio was divided by the each patient’s body height (m) to
produce the corrected splenic length-platelet ratios. In addition, the splenic volume index-to-
platelet count ratio was divided by the patient’s body weight (kg) to produce a corrected ratio.
Results: The corrected splenic length-platelet ratio was more significantly increased in 21
patients with esophageal variceal bleeding (Group A) than in nine patients without variceal
bleeding [(Group B) 0.98  0.64 vs. 0.44  0.18, p < 0.01]. The splenic volume index-to-platelet
count ratio corrected by body weight was significantly larger in Group A (510.7  536.2) than in
Group B (148.188.9, p < 0.01).of Medical Imaging, Medical College and Hospital, National Taiwan University, 7 Chung-Shan South
w (S.S.-F. Peng).
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MR of esophageal varices in BA 483Conclusion: Less-invasive indices, including the corrected splenic length platelet ratio and the
splenic volume index-to-platelet count ratio, may be valuable predictors of esophageal variceal
bleeding in patients with biliary atresia.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Table 1 Demographic and laboratory data, Child-Turcotte-
Pugh score, pediatric end-stage liver disease or model of
end-stage liver disease score and clinical findings.
Sex (Male/Female) 10/20
Age at Kasai operation, d 62  23
Body weight at MRI (kg) 16.0  14.9
Bilirubin (g/dl) 10.2  6.7
Albumin (mg/dl) 3.67  0.43
Prothrombin time (second) 13.1  2.7
Platelet count (1000/mm3) 218  157
Child-Turcotte-Pugh score 8  1 (5e10)
Child-Turcotte-Pugh class (A/B/C) 5/23/2
Pediatric end-stage liver disease or
model of end-stage liver disease score
12  8 (5e28)
Esophageal varices () 9/21
Shifting dullness () 24/6
MRI Z magnetic resonance imaging.Introduction
Biliary atresia (BA) is a progressive fibro-obliterative chol-
angiopathy that affects the extra- and intrahepatic biliary
tree, resulting in fibrous obliteration of the biliary tract
and the subsequent development of biliary cirrhosis. The
development of the Kasai portoenterostomy procedure
improves the prognosis and prolongs the lives of children
with BA. However, portal hypertension still develops, even
after the Kasai operation.1,2 More than 40% of the long-term
survivors had cirrhosis and/or portal hypertension.2 Vari-
ceal bleeding is a common and life-threatening complica-
tion of portal hypertension in BA patients, displaying the
highest mortality rate.1e5
Because esophageal variceal hemorrhaging can be
devastating, the early diagnosis and follow-up of esopha-
geal varices are mandatory in the postoperative care of
patients with BA.6,7 Several studies suggest less-invasive
parameters for predicting the presence of esophageal
varices in adults with liver cirrhosis,8e28 but their validity in
children with biliary cirrhosis is uncertain and has rarely
been assessed. There have been few reports about less-
invasive parameters for predicting esophageal variceal
bleeding in patients with BA.7 Therefore, this study was
conducted with an aim of evaluating the feasibility of less-
invasive magnetic resonance imaging (MRI) indices as indi-
cators of the presence of esophageal variceal bleeding.
Patients and methods
Patient population
In this retrospective study, 31 patents with pathologically
proven BA diagnoses and without cardiac anomalies
received MR examinations from January 2006 to June 2010.
One of the 31 patients had moderate ascites was excluded
to avoid overestimating body weight. The 30 patients,
consisted of 11 boys and 19 girls, underwent Kasai por-
toenterostomy between the ages of 26 and 147 (62  23)
days. MR examinations were performed at the age of
108e5314 days (median, 285 days). The 30 patients
received abdominal MR examinations 33e5137 (median,
195) days after the Kasai operation, including 13/30
patients to look for possible complications of biliary
cirrhosis and 17/30 patients for anatomic evaluation before
liver transplantation. A patient received the Kasai opera-
tion at the age of 147 days and underwent an MR exami-
nation 33 days later due to persistent jaundice and
a suspicion of portal hypertension. The summarized clinical
demographic data of the 30 patients are listed on Table 1.
This study was conducted according to a protocol approved
by the Committee of Research Ethics of the National Taiwan
University Hospital (201010044R).Criteria for esophageal variceal bleeding
The 30 patients were subdivided into Groups A and B. The
Group A patients had clinical signs of gastrointestinal
bleeding and F1eF3 esophageal varices detected by pan-
endoscopic examinations. Those patients without signs of
gastrointestinal bleeding or esophageal varices on pan-
endoscopy belonged to group B. A standard flexible gas-
trofiberscope (XP240 or XP260, Olympus, Tokyo, Japan)
was used for a panendoscopic examination, no more than
4 months either before the MR examination, or after it. A
total of 23 patients with clinical findings related to gastro-
intestinal bleeding (including fecal occult blood) received
panendoscopic examinations. In two of the 23 patients with
fecal occult blood, panendoscopic revealed no evident
esophageal varices. A total of 21 patients had F1eF3
esophageal varices, according to Beppu classification,29
confirmed by panendoscopic findings and were included in
patient Group A. Among the 21 patients, seven patients had
red color signs on the observed esophageal varices and the
other 14 patients received variceal treatment including
alcohol sclerosing therapy (n Z 1), ligation (n Z 7), and
banding (nZ 6). The latter 14 patients had diminished fecal
occult blood after variceal treatment. In Group A, nine of
the 21 patients were younger than 1 year of age.
The other seven of the 30 patients were younger than
2 years of age and had negative results of examinations of
stool occult blood for at least one time. Four of the seven
patients underwent living-related transplantation 2e6
months after MR examinations. Three of the seven patients
received examinations of fecal occult blood every 6 months
after the MR examinations for 20e40 months. The nine
patients, including two with negative panendoscopic findings
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were included in Group B.
Child-Turcotte-Pugh, pediatric end-stage liver
disease, and model of end-stage liver disease
scores
All clinical and laboratory data, including sex, age, body
weight (kg), body height (cm), bilirubin level (g/dl),
albumin level (mg/dl), prothrombin time (seconds), inter-
national normalized ratio (INR), and platelet counts
(/mm3), were obtained within 1 month before or after the
MR examination. The Child-Turcotte-Pugh (CTP) score30 was
calculated using five variables: ascites, encephalopathy,
bilirubin, albumin, and prothrombin time. The presence of
ascites was diagnosed according to physical findings of
shifting dullness. Values of 1, 2, or 3 were assigned to each
of these variables to represent increasing severity, and
a score was calculated as the sum of the five variables for
each patient. A CTP score less than 7 was considered to be
Class A; from 7e9 was Class B, while any score greater than 9
was Class C. The pediatric end-stage liver disease (PELD)
scores31,32 were calculated according to the following
formula detailed in the homepage of the United Network
for Organ Sharing (UNOS), and they were then multiplied
by ten and rounded to the nearest integer, PELD score Z
0.480  Loge (bilirubin mg/dL) þ 1.857  Loge (INR) e
0.687  Loge (albumin g/dL) þ 0.436, if the patient is less
than 1 year of age [scores for patients listed for liver trans-
plantation before the patient’s first birthday continued to
include the value assigned for age (< 1 year) until the patient
reached the age of 24months], andþ 0.667 if the patient has
growth failure (< e2 standard deviations).
Model of end-stage liver disease (MELD) scores31 were
calculated using the following formula:
MELD scoreZ0:957 Logeðcreatinine mg=dLÞ þ 0:378
 Logeðbilirubin mg=dLÞ þ 1:120
 LogeðINRÞ þ 0:6431
The PELD and MELD scores were multiplied by ten and
rounded to the nearest whole number.
According to the latest UNOS modifications, laboratory
values below 1.0 were rounded to 1.0 to avoid negative
scores, and the maximum serum creatinine considered in
the MELD equation was 4.0 mg/dL.
MRI
MRIwas performedwith a 1.5-tesla scanner (SignaMagnetom;
GE Medical Systems, Milwaukee, WI, USA) using a phased-
array torso. Out of the 31 patients younger than 6 years of
age, 23 took chloral hydrate (National Taiwan University
Hospital) per os with a dosage of 0.5 mg/kg body weight
10e45 minutes before their MRI examination. Proton-
weighted imaging included the following sequences: fast
spin-echo 4000-5000/8-12 (repetition time millisecond/echo
time millisecond) with an imaging matrix of 256  192 or
256 pixels, a flip angle of 120e150, an echo-train length of 20,
and one acquisition. T2-weighted imaging included the
following sequences: breathing-averaged fast spin echo [timeto repeat (TR)/time to echo (TE) Z 3000-7000/90-100
millisecond (ms)] and breath-hold fast spin-echo (TR/
TEZ 2000e4000/70e100 ms) with a flip angle of 60e90, an
echo-train length of 20, and one acquisition. T1-weighted
spin-echo, breath-averaged (TR/TE Z 500-700/10e20 ms,
flip angle 90) images were also obtainedwith fat saturation in
the coronal plane after using a contrast medium. The imaging
matrixwas 256 192 or 256 pixels for T2- and proton-weighed
images and 512  512 for T1-weighted images. The slice
thickness of proton-weighted, T2-weighted and T1-weighted
images was 5 mm with an intersection gap of 1.5 mm.
Image measurement
The liver was divided into the left and right lobar (left
medial, left lateral) and caudate regions. The caudate
region was demarcated by an imaginary line connecting the
bifurcation of the main portal vein and the right lateral
border of the inferior vena cava. The measurements of
the length or long and short axes (cm) of the left lobar,
left medial, lateral, caudate hepatic regions and spleen
were obtained from axial MRI according to previously
described methods.28,30 On the coronal T1-weighted
spin-echo images, the largest cephalocaudal height (cm)
of the spleen, left lobar, left medial, lateral, and caudate
regions of the liver were measured. All three-axial length
measurements of the hepatic regions and spleen were
typically made within 1 cm of the level of the left umbilical
portal vein and splenic hilum (Fig. 1A and B), respectively.
Volume indices were calculated according to Ito and
colleagues30 as a simple product of these three diameters
(cm) for the spleen and each region of the liver; i.e., (long-
axis length)  (short-axis width)  (cephalocaudal height).
These indices did not provide the exact measurements of
hepatic regional or splenic volumes but gave an estimate
based on the sizes of the hepatic regions. However, splenic
measurement was not performed in one Group A patient
who had received a splenectomy 1 year before MRI.
Less-invasive indices
We chose one measurement and five calculated ratio
indices, including the maximal length of spleen (cm), the
splenic length (cm)/platelet count (1000/mm3) ratio (SLPR),
the splenic volume index/platelet count (1000/mm3) ratio
(SVIPR), the volume index of the caudate lobe/albumin
level (mg/dl) ratio, and the volume index of the left hepatic
lobe/albumin level (mg/dl) ratio. To take the effect of age-
related body weight and height into consideration, the
splenic length and SLPR were further divided by the body
height of each patient’s body weight (kg) to produce a cor-
rected splenic length and SLPR. In addition, the SVIPR, the
volume index of caudate lobe-albumin level ratio and the
volume index of the left hepatic lobe-albumin level ratio
were divided by each patient’s body weight to produce the
corresponding corrected ratio indices.
Statistical analysis
All of the data were analyzed using Stata 8.0 software
(IBM, Bryan, Texas, USA) and a p value less than 0.05 was
Figure 1 A 1482-day-old boy with biliary atresia after
receiving Kasai operation. His platelet count was 66,000/mm3
and his body weight and body height was 13 kg and 0.94 m,
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biochemical data, imagemeasurements and ratio indices, as
well as the analysis of ordinal data such as sex, age, and score
results, was performed using a Mann-Whitney rank-sum test.
Multiple regression using an enter method of logistic model
to include splenic length, splenic, and hepatic indices of BA
patients with and without esophageal varices was per-
formed. Sensitivity and specificity, as well as the best cut-off
values for age, image measurements and index ratios for
detecting the presence of esophageal variceal bleeding,
were calculated using receiver operating characteristic
(ROC) curves.
Results
The demographic parameters, image measurements, and
less-invasive indices were correlated with the presence of
esophageal variceal bleeding and listed in Table 2. Group A
patients with esophageal variceal bleeding (Fig. 1C) were
significantly older than Group B (1774  1767 days vs.
219  99 days, p < 0.01). The body weight and body height
of patients in Group A (20.0  16.3 kg and 0.98  0.41 m)
were significantly heavier and higher than that those
assigned to Group B (6.8  1.6 kg and 0.64  0.07, pZ 0.04
and 0.04, respectively). These results are shown in Table 2.
In addition, Group A patients (198  159 1000/mm3) had
higher platelet counts than Group B (310  145 1000/mm3,
p < 0.01). However, CTP, PELD, and MELD scores, and the
age when Kasai operation was performed did not vary
significantly between patients in Groups A or B. None of the
23 chloral hydrate-sedated patients experienced respira-
tory distress or involuntary movement during MRI or within
30 minutes after it.
The length of the spleen in Group A patients (100.2 
34.2 cm) was significantly longer than in group B patients
(72.4  12.6 cm; pZ 0.02). These results are also shown in
Table 2. The SLPR was significantly larger in Group A than in
Group B (1.071  1.153 vs. 0.298 þ 0.125, p < 0.01). After
being corrected by the body height, the corrected SLPR
was still significantly larger in Group A than in Group B
(0.98  0.64 vs. 0.44  0.18, p < 0.01).
Before correction by the body weight, the SVIPR was
significantly larger in Group A patients (14171  25694)
than Group B patients (1226  839, p < 0.01). The ratios of
the volume indices of both the caudate segment and the
left hepatic lobe over the albumin level were also signifi-
cantly larger (Fig. 1A and B) in Group A (19835  28980 and
110672  83310, respectively) than Group B (4529  3461
and 55598  25283, pZ 0.04 and 0.02, respectively). Afterrespectively, 4 days before the magnetic resonance imaging
(MRI) examination. (A) axial fast-spin echo T2-weighted image;
(B) spin-echo T1-weighted image in the coronal plane. The
splenic length is 110.7 mm and the splenic volume index is
862.995. The corrected splenic length-platelet count and
splenic volume index-platelet count ratios are 1.78 and 1.0058,
respectively; (C) varices with red color signs (arrows) and
a submucosal varix (arrowheads) are disclosed by a panendo-
scopy within the lower thoracic esophagus at a depth of 20 cm
from the incisor three months after MRI examination.
Table 2 Comparison of demographic, laboratory data, Child-Turcotte-Pugh, pediatric end-stage liver disease or model of end-
stage liver disease scores, splenic length, splenic and hepatic indices of biliary atresia patients with and without esophageal
varices.
Esophageal varices p value
(þ) ()
Sex
Male 7 4 0.69
Female 14 6
Age, d 1774  1767 219  99 <0.01*
Age when Kasai operation performed, d 66  26 54  9 0.49
Bilirubin (g/dl) 9.8  7.7 10.9  3.4 0.53
Body weight (kg) 20.0  16.3 6.8  1.6 0.04*
Body height (m) 0.98  0.41 0.64  0.07 0.04*
Albumin (mg/dl) 3.58  0.44 3.86  0.39 0.07
Prothrombin time (second) 13.6  3.0 11.8  1.4 0.13
Platelet count (1000/mm3) 198  159 310  145 <0.01
Child-Turcotte-Pugh score 8  2 7  1 0.62
Pediatric end-stage liver disease or model
of end-stage liver disease score
11  9 12  5 0.96
Length of spleen (mm) 100.2  34.2 72.4  12.6 0.02*
Length of spleen (mm)/body height (m) 11.23  2.26 11.16  2.81 0.56
Splenic length (mm)/platelet count (K) 1.071  1.153 0.298  0.125 <0.01*
Splenic length/body height (m)/platelet count 0.98  0.64 0.44  0.18 <0.01*
Splenic volume index (mm3)/platelet count 14,171  25,694 1226  839 <0.01*
Splenic volume index/body weight (kg)/platelet count 510.7  536.2 148.1  88.9 <0.01*
Volume index of caudate segment/albumin level 19,835  28,980 4529  3461 0.04*
Volume index of caudate segment/albumin level/body weight 918  750 701 þ 554 0.50
Volume index of left hepatic lobe/albumin level 110,672  83,310 55,598  25,283 0.02*
Volume index of left hepatic lobe/albumin level/body weight 7152  4141 9636  4462 0.16
* Z a p-value <0.05, indicating a statistically significant difference.
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SVIPR was significantly larger in Group A (510.7  536.2)
than Group B (148.1  88.9, p < 0.01).
When the factors including age, body weight, length of
spleen, SLPR, corrected SLPR, SVIPR, corrected SVIPR, andTable 3 Summary of splenic length, splenic and hepatic indices
using the enter method of the logistic model.
Factor Coefficient
Age 0.018
Body weight (kg) 0.405
Platelet count (1000/mm3) 0.002
Length of spleen (mm) 1.413
Splenic length/platelet count 207.031
Splenic length/body height (m)/platelet count 182.929
Splenic volume index/platelet count 0.921
Splenic volume index/body weight/platelet count 0.034
Volume index of caudate segment/albumin level 0.129
Volume index of left hepatic lobe/albumin level 0.010
Constant 1.479
Global Model chi-square score X2 Z 31.146;
Goodness of fit X2 of Hosmervolume indices of both the caudate segment and the left
hepatic lobe over albumin level were analyzed by enter
method of logistic model (Table 3), only the corrected SLPR
significantly predict the odds ratio of BA patients without











0.045 0.159 1 0.690 0.982
0.974 0.173 1 0.678 1.989 Cox and Snell
R2 Z 0.658
0.024 0.005 1 0.941 0.998 Nagelkerke
R2 Z 0.927
1.699 0.692 1 0.405 4.109
359.963 0.331 1 0.565 0.000
90.524 4.084 1 0.043 0.000
1.136 0.658 1 0.417 2.513
0.043 0.630 1 0.428 1.035
0.136 0.887 1 0.346 0.879
0.043 0.057 1 0.811 1.010
10.368 0.020 1 0.887 4.387
p Z 0.001
-Lemeshow test Z 1.874, p Z 0.985
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curve Z 1) showed significant discrimination between the
patients in Groups A and B. A threshold of 0.506 was sug-
gested for the corrected SLPR to achieve a specificity of 89%
and a sensitivity of 100%. The area under curve of age was
0.67 and cut-off value of the age to be 195 days to reach
the sensitivity of 85%.Discussion
Even after a successful Kasai portoenterostomy, biliary
cirrhosis can still progress in BA patients and induce
esophageal varices. About two-thirds of BA children will
have endoscopically visible esophageal varices by the time
they are 2e3 years of age, and half of these will eventually
bleed to death.1,3e5 Because long-term survivors of BA are
increasing, prompt and adequate management of esopha-
geal varices is becoming increasingly important for the
follow-up of postoperative BA patients to avoid serious and
potentially devastating bleeding complications.4,33
A panendoscopy is currently the mainstay for diagnosing
esophageal varices. However, there is no consensus on the
timing for screening BA patients without signs related to
esophageal varices.7 In addition, a panendoscopy carries
higher risk and entails more medical burden when per-
formed on children than on adults because of the inva-
siveness of the procedure, anesthesia-related risks, and
hospitalization costs. The treatment of esophageal variceal
bleeding in children usually begins only after the first
episode of gastrointestinal bleeding.33 Our present protocol
suggests that a panendoscopy be performed in patients
without signs of gastrointestinal bleeding or portal hyper-
tension after 2 years of age. However, our results suggested
the cut-off value of the age to be 195 days to reach the
sensitivity of 85%. A panendoscopy could be performed as
early as 195 days to find out the asymptomatic esophageal
varices earlier than before.
In some studies, PELD and MELD scores have been proven
useful for assessing the severity of pediatric liver diseases,
including that of BA.34 However, neither the CPT nor the
PELD/MELD score was significantly associated with the
presence of esophageal variceal bleeding in our series. As
a result, the severity of biliary cirrhosis as assessed by these
two scores was not satisfactory in distinguishing Group A
from Group B.14,34
A less-invasive procedure for identifying esophageal
variceal bleeding will assist in determining the risk of var-
iceal bleeding, choosing the optimal time to perform an
endoscopy and avoiding potentially life-threatening vari-
ceal bleeding in children. Abdominal ultrasonography is the
frequently used first-line modality to follow up the hepatic
or splenic lesions in BA patients. However, it could be
difficult to measure the exact three-dimensional diameters
on a single ultrasonographic image when the spleen is huge.
Most of the previously reported MR or computed tomo-
graphic measurements and parameters related to esopha-
geal varices derive from studies of hepatitis-related
cirrhotic adult patients.8e28,30 However, adults and chil-
dren are different in many ways and direct extrapolation of
data related to esophageal variceal hemorrhages from
adults to children may be unreliable.33Because BA is a progressive disease, increasing age leads
to higher incidence of esophageal variceal bleeding.
However, age per se was not the only determinant of the
development of esophageal variceal bleeding. The age
when BA patients under Kasai operation were not signifi-
cantly different between group A and B patients but the
study did not include all the BA patients receiving Kasai
operation during the study period. Similar to previous
studies of cirrhotic adults, the ratio of the length of the
spleen or the splenic volume index to the platelet count
had high sensitivity for predicting the presence of esopha-
geal variceal bleeding in BA.8,9,11e13 Decreases in platelet
count and increases in splenic length could be attributed to
aggravated hypersplenism caused by progressing portal
hypertension. In addition, the ratios of the volume indices
of the caudate segment and left lobe to the albumin level
were also significantly larger in patients with esophageal
variceal bleeding.35 The differences in the volume index-
related ratios could partially relate to the differences in
body weight between the Group A and Group B patients in
our series. Since previous studies proposed that visceral
organ weights increase with the total body weight in human
neonates to adults,36 we divided the SLPR and SVIPR by the
body height and body weight, respectively, to obtain cor-
rected ratios with sensitivity 100% for corrected SLPR. The
SLPR per body height may be a good screening criterion
irrespective of patient’s age. Our two patients received an
MR examination 1 and 3 months before the first attack of
esophageal variceal bleeding. As a result, the less-invasive
MR indices may be promising in predicting the presence of
esophageal varices before a catastrophic hemorrhagic
event.
Our study, however, has several limitations, including
a small sample size and the possible overestimation of the
exact incidence of esophageal variceal bleeding, because
of possible concomitant bleeding from other gastrointes-
tinal lesions. The indications and time-point of MRI exami-
nations relative to panendoscopy and Kasai operation were
quite heterogeneous in this retrospective study. Despite
a good correlation between the corrected SLPR and the
presence of esophageal variceal bleeding, it is difficult
to rely on these indices alone to exclude patients from
an initial screening endoscopy, especially patients with
a remarkable weight gain due to a large amount of ascites.
However, they may help to identify patients who could
benefit from more frequent endoscopic follow-ups, espe-
cially in asymptomatic patients older than 195 days. The
prospective use of less-invasive MR indices for screening of
a well-selected group of BA patients could further validate
the less-invasive indices. Although MRI examinations are
expensive and sedation is usually necessary for uncooper-
ative patients, measurement of corrected SLPR in BA
patients with biliary or vascular complications requires no
additional use of contrast medium and carries no increased
risks but gives some clinical implication to further prophy-
lactic measures.
In conclusion, indices including the SLPR per body
height may be good predictors of esophageal variceal
bleeding in patients with BA. We suggest that these easily
accessible, less-invasive indices be used to help to identify
BA patients who could benefit from earlier endoscopic
follow-ups.
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